AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35462033 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 150
Study 33501978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 284
Study 33501978 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 284
Study 35048423 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ-009 (2 mg)
Number of subjects: 25
Study 35048423 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ-009 (3 mg)
Number of subjects: 25
Study 35048423 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ-009 (4 mg)
Number of subjects: 25
Study 35048423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 33268527 — intervention group
Group type: COMPARATOR
Intervention: Active conventional treatment (either prednisolone tapered to 5 mg/day, or sulfasalazine combined with hydroxychloroquine and intra‐articular corticosteroids)
Number of subjects: 812
Study 33268527 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 812
Study 33268527 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 812
Study 33268527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 812
Study 35819787 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention
Number of subjects: 252
Study 35819787 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 252
Study 33024022 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA)
Number of subjects: 0
Study 33024022 — intervention group
Group type: COMPARATOR
Intervention: Interferon Beta-1a (IFN‐β‐1a)
Number of subjects: 0
Study 34800699 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Youth by Youth (4YBY) implementation strategy
Number of subjects: 0
Study 33771941 — intervention group
Group type: EXPERIMENTAL
Intervention: 8/4 self-paced interval training session
Number of subjects: 11
Study 33771941 — intervention group
Group type: EXPERIMENTAL
Intervention: 4/2 self-paced interval training session
Number of subjects: 11
Study 32176006 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraorbital region taping (TG)
Number of subjects: 64
Study 32176006 — intervention group
Group type: COMPARATOR
Intervention: Nontaping group (Control)
Number of subjects: 64
Study 35810757 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct endovascular thrombectomy
Number of subjects: 295
Study 35810757 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy (intravenous thrombolytic before endovascular thrombectomy)
Number of subjects: 295
Study 35810757 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy
Number of subjects: 295
Study 33780749 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational-motivational intervention (physician-led integrated intervention with educational session and motivational interviewing phone sessions)
Number of subjects: 360
Study 33780749 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 360
Study 33780749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 360
Study 34155159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine (DEX) administered at an initial dose of 1 µg/kg over 10 minutes, followed by a continuous infusion at 0.4 μg/kg/h until 30 minutes before the end of surgery.
Number of subjects: 90
Study 34155159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral superficial cervical plexus block (SCPB) with 10 mL of 0.375% ropivacaine injected on each side.
Number of subjects: 90
Study 34155159 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline administered at the same rate and dose as in group D.
Number of subjects: 90
Study 616684303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheathless common 7-F guiding catheter
Number of subjects: 160
Study 616684303 — intervention group
Group type: COMPARATOR
Intervention: Conventional 6-F sheath guiding catheter
Number of subjects: 160
Study 35139044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal chloroprocaine 49.5 mg with fentanyl 10 ug
Number of subjects: 45
Study 33027448 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational programme on cardiovascular prevention for children; exposure for one year
Number of subjects: 418
Study 33027448 — intervention group
Group type: COMPARATOR
Intervention: Written cardiovascular health educational brochures for parents (Control)
Number of subjects: 418
Study 36188435 — intervention group
Group type: EXPERIMENTAL
Intervention: RQ3013 (30 μg mRNA per 0.15 mL)
Number of subjects: 235
Study 36188435 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdTS-S (5×10^10 viral particles per 0.5 mL)
Number of subjects: 235
Study 36188435 — intervention group
Group type: EXPERIMENTAL
Intervention: ZR202-CoV (25 μg per 0.5 mL)
Number of subjects: 235
Study 36188435 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (3 μg inactivated CN02 strain of SARS-CoV-2 per 0.5 mL)
Number of subjects: 235
Study 36188435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mL of 0.9% sodium chloride solution)
Number of subjects: 235
Study 33452059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-focused CBT delivered by diabetes specialist nurses (10 sessions over 12 months)
Number of subjects: 71
Study 33452059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-focused CBT
Number of subjects: 71
Study 33212268 — intervention group
Group type: EXPERIMENTAL
Intervention: Violet LED
Number of subjects: 90
Study 33212268 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 % hydrogen peroxide
Number of subjects: 90
Study 33212268 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 % hydrogen peroxide + violet LED
Number of subjects: 90
Study 33212268 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 % carbamide peroxide
Number of subjects: 90
Study 33212268 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 % carbamide peroxide + violet LED
Number of subjects: 90
Study 33212268 — intervention group
Group type: COMPARATOR
Intervention: No bleaching (control)
Number of subjects: 90
Study 33078466 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated monochorionic twin pregnancies
Number of subjects: 3873
Study 33078466 — intervention group
Group type: COMPARATOR
Intervention: Dichorionic twin pregnancies
Number of subjects: 3873
Study 35182121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical perforated pessary (CPP)
Number of subjects: 0
Study 35182121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pessary)
Number of subjects: 0
Study 33461539 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery associated with actual practice
Number of subjects: 40
Study 33461539 — intervention group
Group type: COMPARATOR
Intervention: Real practice only (Control)
Number of subjects: 40
Study 32737344 — intervention group
Group type: EXPERIMENTAL
Intervention: More years of schooling
Number of subjects: 0
Study 35630045 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (warm-up, aerobic training, strength training, stretching, cool down)
Number of subjects: 91
Study 35630045 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (warm-up, strength training, aerobic training, stretching, cool down)
Number of subjects: 91
Study 35630045 — intervention group
Group type: COMPARATOR
Intervention: Control Group C (no exercise)
Number of subjects: 91
Study 32975556 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 180
Study 32975556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 32466678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap�s Saludables Ni�os Saludables intervention
Number of subjects: 36
Study 33580340 — intervention group
Group type: COMPARATOR
Intervention: α‐tocopherol 0 IU
Number of subjects: 20
Study 33580340 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐tocopherol 40 IU
Number of subjects: 20
Study 33580340 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐tocopherol 70 IU
Number of subjects: 20
Study 33580340 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐tocopherol 90 IU
Number of subjects: 20
Study 35633654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 60
Study 35633654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin+Traditional Chinese Medicine (TCM)
Number of subjects: 60
Study 35633654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin+Metformin
Number of subjects: 60
Study 33918630 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient intervention (not specified in detail)
Number of subjects: 100
Study 32789480 — intervention group
Group type: EXPERIMENTAL
Intervention: PCb (paclitaxel 80 mg/m2 and carboplatin [AUC = 2] on days 1, 8, and 15 every 28 days for 6 cycles)
Number of subjects: 647
Study 32789480 — intervention group
Group type: COMPARATOR
Intervention: CEF-T (cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2, and fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles)
Number of subjects: 647
Study 32789480 — intervention group
Group type: EXPERIMENTAL
Intervention: PCb
Number of subjects: 647
Study 35762659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 803
Study 35762659 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 803
Study 35869929 — intervention group
Group type: EXPERIMENTAL
Intervention: HDIT101 (doses up to 12,150 mg)
Number of subjects: 24
Study 36162740 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT IVR
Number of subjects: 25
Study 33503610 — intervention group
Group type: EXPERIMENTAL
Intervention: One Strength Group (3 injections with 1 strength B, 10,000 TU/mL)
Number of subjects: 87
Study 33503610 — intervention group
Group type: COMPARATOR
Intervention: Standard group (7 injections with 2 strengths A (1,000 TU/mL) and B (10,000 TU/mL))
Number of subjects: 87
Study 32833762 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting as bridge‐to‐surgery (SBTS)
Number of subjects: 115
Study 32833762 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting as bridge‐to‐surgery (SBTS) (descending colon obstruction)
Number of subjects: 115
Study 32833762 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgery (ES)
Number of subjects: 115
Study 33070326 — intervention group
Group type: EXPERIMENTAL
Intervention: Water as a neutralising agent
Number of subjects: 126
Study 33070326 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate plus solution (Control)
Number of subjects: 126
Study 34128822 — intervention group
Group type: EXPERIMENTAL
Intervention: MyBackPain website access
Number of subjects: 453
Study 34128822 — intervention group
Group type: COMPARATOR
Intervention: Unguided internet use
Number of subjects: 453
Study 35024596 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/d)
Number of subjects: 35
Study 35024596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 34548195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue engineered construct (collagen/osteogenically differentiated bone marrow‐derived mesenchymal stem cells)
Number of subjects: 10
Study 34548195 — intervention group
Group type: COMPARATOR
Intervention: Autogenous anterior iliac crest (AIC) bone graft
Number of subjects: 10
Study 34515079 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic medicine (OM) sessions (up to six sessions) in addition to routine care
Number of subjects: 40
Study 32569934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soybean (FS)
Number of subjects: 0
Study 32569934 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented soybean (NFS)
Number of subjects: 0
Study 35883102 — intervention group
Group type: EXPERIMENTAL
Intervention: GRIPP intervention program (6 exercises, maximum total of 10 min)
Number of subjects: 308
Study 35883102 — intervention group
Group type: COMPARATOR
Intervention: Usual warm-up
Number of subjects: 308
Study 35883102 — intervention group
Group type: EXPERIMENTAL
Intervention: GRIPP intervention program
Number of subjects: 308
Study 32993637 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D‐3L
Number of subjects: 224
Study 32993637 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D‐5L
Number of subjects: 224
Study 32993637 — intervention group
Group type: COMPARATOR
Intervention: Barthel Index
Number of subjects: 224
Study 36077145 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (200 µg or 8000 IU)
Number of subjects: 29
Study 36077145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 33407848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI) including one face-to-face counseling session incorporating cognitive behavioral therapy and 30 days of 2-way text messaging
Number of subjects: 25
Study 33407848 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) counseling
Number of subjects: 25
Study 33407848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI)
Number of subjects: 25
Study 616120584 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA/riboflavin corneal collagen crosslinking (CXL)
Number of subjects: 44
Study 35750731 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet with visual aids
Number of subjects: 99
Study 35750731 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet with no visual aids
Number of subjects: 99
Study 35750731 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information only
Number of subjects: 99
Study 35750731 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet with visual aids)
Number of subjects: 99
Study 35750731 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 99
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed clinical depression
Number of subjects: 538
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild depression symptoms
Number of subjects: 538
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence to antihypertensive medications (AHTNM)
Number of subjects: 538
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care system support
Number of subjects: 538
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of antihypertensive medications (AHTNM)
Number of subjects: 538
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 538
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Better social support
Number of subjects: 538
Study 34158786 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger patient-doctor relationship
Number of subjects: 538
Study 32265309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Aztreonam
Number of subjects: 0
Study 34210211 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level construal task
Number of subjects: 135
Study 34210211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level construal task
Number of subjects: 135
Study 34210211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous health communication
Number of subjects: 135
Study 34210211 — intervention group
Group type: EXPERIMENTAL
Intervention: Unambiguous health communication
Number of subjects: 135
Study 34315508 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training with Flexibar® (9 min daily for 12 weeks)
Number of subjects: 71
Study 34315508 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive training with Flexibar® (9 min daily for 12 weeks) and at least 40 min running or walking/week with XCO®
Number of subjects: 71
Study 35809206 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 124
Study 35809206 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (SS)
Number of subjects: 124
Study 35213109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐Level Light Amplification by Stimulated Emission of Radiation therapy (LLLT) using Diode LASER
Number of subjects: 21
Study 35213109 — intervention group
Group type: COMPARATOR
Intervention: Topical Anginovag spray medication
Number of subjects: 21
Study 35213109 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with motivation and follow‐up
Number of subjects: 21
Study 32145713 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intubated anaesthesia combined with paravertebral nerve block (PVNB)
Number of subjects: 60
Study 32145713 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with tracheal intubation (control)
Number of subjects: 60
Study 32519248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with white collar occupation and secure attachment
Number of subjects: 208
Study 32519248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient exhibiting avoidant attachment behaviors
Number of subjects: 208
Study 34792562 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFi (infliximab)
Number of subjects: 95
Study 34792562 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IL-6 (tocilizumab)
Number of subjects: 95
Study 34792562 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA4-Ig (abatacept)
Number of subjects: 95
Study 34792562 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD20 (rituximab)
Number of subjects: 95
Study 34792562 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV levels at month 3
Number of subjects: 95
Study 34792562 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV cut-off level of 1.2 × 10^6 c/ml at month 3
Number of subjects: 95
Study 34062027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nebulized salbutamol (0.15 mg/kg 2–4 h intervals) with oral prednisolone (2 mg/kg/d for 3 days)
Number of subjects: 95
Study 34062027 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand inhaled salbutamol with oral prednisolone (2 mg/kg/d for 3 days)
Number of subjects: 95
Study 34062027 — intervention group
Group type: COMPARATOR
Intervention: High-dose nebulized salbutamol (0.15 mg/kg 2–4 h intervals) with placebo
Number of subjects: 95
Study 34062027 — intervention group
Group type: COMPARATOR
Intervention: On-demand inhaled salbutamol with placebo
Number of subjects: 95
Study 32204977 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg (low-carbohydrate protein-rich bedtime snack)
Number of subjects: 15
Study 32204977 — intervention group
Group type: COMPARATOR
Intervention: Yogurt (high-carbohydrate protein-rich bedtime snack)
Number of subjects: 15
Study 32204977 — intervention group
Group type: COMPARATOR
Intervention: No Bedtime Snack
Number of subjects: 15
Study 35922816 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (n=20)
Number of subjects: 30
Study 35922816 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo; n=10)
Number of subjects: 30
Study 35922816 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 30
Study 35922816 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 30
Study 32168067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg per day)
Number of subjects: 37
Study 32168067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 37
Study 35485186 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus Pain Neuroscience Education (PNE)
Number of subjects: 127
Study 35485186 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 127
Study 35485186 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus PNE
Number of subjects: 127
Study 34788298 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 self‐help instructions (5:2SH)
Number of subjects: 300
Study 34788298 — intervention group
Group type: COMPARATOR
Intervention: Standard Brief Advice (SBA)
Number of subjects: 300
Study 34788298 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 group support (5:2G)
Number of subjects: 300
Study 32212089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus Metformin (arm A)
Number of subjects: 80
Study 32212089 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone (arm B)
Number of subjects: 80
Study 32212089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low VEGF and HIF‐1 α plasma levels
Number of subjects: 80
Study 32212089 — intervention group
Group type: EXPERIMENTAL
Intervention: High expressions of VEGF and HIF in HCC tissue
Number of subjects: 80
Study 32402609 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely supervised cranial electrical stimulation (CES) for 10 daily sessions (60 min each) over two weeks
Number of subjects: 30
Study 32402609 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely supervised cranial electrical stimulation (CES)
Number of subjects: 30
Study 32402609 — intervention group
Group type: COMPARATOR
Intervention: Sham cranial electrical stimulation (CES)
Number of subjects: 30
Study 35719338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose VA therapy (amoxicillin 1 g t.i.d. and VPZ 20 mg b.i.d.)
Number of subjects: 119
Study 35719338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose VA therapy (amoxicillin 1 g b.i.d. and VPZ 20 mg b.i.d.)
Number of subjects: 119
Study 35719338 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori-negative patients)
Number of subjects: 119
Study 35708885 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg once-daily plus obinutuzumab
Number of subjects: 274
Study 33759753 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 0
Study 33759753 — intervention group
Group type: COMPARATOR
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 0
Study 34529293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention (twice weekly for 8 months)
Number of subjects: 121
Study 34529293 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 121
Study 32179906 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimatrix mesalazine (combined dose groups, 2.4 or 4.8 g/day)
Number of subjects: 1300
Study 32179906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study 32179906 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimatrix mesalazine
Number of subjects: 1300
Study 35389428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Atezolizumab
Number of subjects: 40